about
Simulated case management of home telemonitoring to assess the impact of different alert algorithms on work-load and clinical decisionsPrognostic value of systolic mitral annular velocity measured with Doppler tissue imaging in patients with chronic heart failure caused by left ventricular systolic dysfunction.Early Indication of Decompensated Heart Failure in Patients on Home-Telemonitoring: A Comparison of Prediction Algorithms Based on Daily Weight and Noninvasive Transthoracic Bio-impedance.Influence of case definition on incidence and outcome of acute coronary syndromesHeart rate achieved or beta-blocker dose in patients with chronic heart failure: which is the better target?Is heart rate important for patients with heart failure in atrial fibrillation?Breathlessness at rest is not the dominant presentation of patients admitted with heart failure.Telehealth for heart failure management: patient empowered self-care or surveillance by the nanny state?Depression as an independent prognostic factor for all-cause mortality after a hospital admission for worsening heart failure.What impact do anxiety, depression, perceived control and technology capability have on whether patients with chronic heart failure take-up or continue to use home tele-monitoring services? Study design of ADaPT-HF.Statistical methods in epidemiology. IX. Survival (failure-time) models.Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease.If home telemonitoring reduces mortality in heart failure, is this just due to better guideline-based treatment?Abnormalities of the ventilatory equivalent for carbon dioxide in patients with chronic heart failure.Relation between severity of left ventricular systolic dysfunction and repolarisation abnormalities on the surface ECG: a report from the Euro heart failure survey.Telemonitoring for heart failure: the only feasible option for good universal care?The prevalence and incidence of left bundle branch block in ambulant patients with chronic heart failure.Predicting hospitalization due to worsening heart failure using daily weight measurement: analysis of the Trans-European Network-Home-Care Management System (TEN-HMS) study.Intelligent model-based advisory system for the management of ventilated intensive care patients. Part II: Advisory system design and evaluation.Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure.The timing of development and subsequent clinical course of heart failure after a myocardial infarction.Elevated glycated haemoglobin is a strong predictor of mortality in patients with left ventricular systolic dysfunction who are not receiving treatment for diabetes mellitus.The in vitro stability of novel cardiovascular and sepsis biomarkers at ambient temperature.A comparison of patient and physician-rated New York Heart Association class in a community-based heart failure clinic.Natriuretic peptides for heart failure. Fashionable? Useful? Necessary?Natriuretic peptides in patients with atrial fibrillation and advanced chronic heart failure: determinants and prognostic value of (NT-)ANP and (NT-pro) BNP.Red cell distribution width: an inexpensive and powerful prognostic marker in heart failure.The diagnostic utility of N-terminal pro-B-type natriuretic peptide for the detection of major structural heart disease in patients with atrial fibrillation.Derivation and validation of a simple clinical risk-model in heart failure based on 6 minute walk test performance and NT-proBNP status--do we need specificity for sex and beta-blockers?Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study.N-terminal brain natriuretic peptide as a screening tool for heart failure in the pacemaker population.Does the physical examination still have a role in patients with suspected heart failure?Identifying patients at risk of death or hospitalisation due to worsening heart failure using decision tree analysis: evidence from the Trans-European Network-Home-Care Management System (TEN-HMS) study.Is taking part in clinical trials good for your health? A cohort study.Predicting peak oxygen uptake from 6-min walk test performance in male patients with left ventricular systolic dysfunction.Development of a composite model derived from cardiopulmonary exercise tests to predict mortality risk in patients with mild-to-moderate heart failurePrevalence of, Associations With, and Prognostic Value of Tricuspid Annular Plane Systolic Excursion (TAPSE) Among Out-Patients Referred for the Evaluation of Heart FailureLimited role for ivabradine in the treatment of chronic heart failureThe prognostic value of individual NT-proBNP values in chronic heart failure does not change with advancing ageRuling out heart failure in primary-care: The cost-benefit of pre-screening using NT-proBNP and QRS width
P50
Q30835186-11172CD3-1C77-443A-81CD-B7D21D162895Q35770870-032B49DB-989E-4047-9A6D-1F3C62011E4FQ36650475-D8D0240C-6EDC-44D7-BCFA-DFBE6563FEBBQ37587389-6535A300-4400-41E4-BF5D-57FD848A695CQ38012561-3C7EA843-03A2-44FD-A221-5855C5856072Q38222202-D40936C9-CA40-4989-B193-574BD4C5B159Q38276145-269B7C45-E736-4A41-979A-66EECB1C48EEQ39204265-06449544-2B10-486E-BDAC-F027A764379EQ39623159-656CABF4-B552-4A3F-966F-B81F3AE65085Q39648341-5AB052B5-6C8F-4F1A-A610-A400559DD4BCQ39911823-413EF082-6392-4BA6-9C5F-3CEFFED03AF4Q40630386-36D1BCC5-811E-4482-ACEB-D8CDE5686A5DQ41232264-39ACE5A8-4121-4BB8-8681-E1ED67562517Q42159851-755CE11F-8018-4601-B662-62E85D3FFD3BQ42832798-DB3A4D40-9DB1-4019-9B05-DB40E5A55BA0Q43178435-D2F6D910-65E9-4917-AED9-D7EFA5EE2DE0Q43858381-6E5053D4-E971-413B-AD66-9F446411EE73Q44147222-5608A47C-AEEA-437C-92BC-0CDD43AE37ACQ44479701-C58CAB61-0535-40B9-A793-F9CBB704897CQ44663275-44FB22F7-23EE-4677-B24C-61B839735085Q44708870-0D46E525-1033-4442-B05A-78C1AB342700Q44850716-CE41C6DC-226F-4818-8012-969D8A4FD3CBQ44899727-A243B57B-43BF-47F1-9A6C-303FFD485087Q45284235-4D1B9859-8E7E-4505-8ED1-2662A38655EEQ48030240-382FF363-895E-4231-A06C-02D5630AFCB0Q48308226-C1728BBE-911B-4D6D-BA59-2860A068D823Q48402812-2AB03724-D79F-4905-A63A-99D28AEC188EQ48428979-15D1022E-77B4-40E2-9875-BD141BAD7230Q48455123-2EC17D1C-C076-4D7C-A9D4-6C9A6D2F777FQ48567006-D262E749-F8B3-4802-927E-A27BE0090DECQ48690103-6A461FD2-B10D-474D-B10A-2051CA7846F9Q48849240-C5543DC5-FCF4-4D34-BF7C-231FA3F2B236Q49092227-B3B97576-740C-4960-9035-07AAAE0016F4Q51606467-C1A0DF1B-599E-477A-8826-FA0B872E7D16Q51963633-893D0689-D60D-4832-A5D8-10F9FD983D1AQ61716521-A10D5906-DDC5-4F9F-9A04-1982397E25F6Q61716575-8DC5BE12-38E9-47FD-9286-5596F2E18DE5Q61716587-851417CF-58BD-4BF9-B6DD-499509A32A6AQ61716629-8275E0D2-C175-4E79-8A7C-88A90EA38112Q61716646-DC456410-8C97-45B4-ADE0-D97CE393CCD4
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Kevin M. Goode
@ast
Kevin M. Goode
@en
Kevin M. Goode
@es
Kevin M. Goode
@nl
Kevin M. Goode
@sl
type
label
Kevin M. Goode
@ast
Kevin M. Goode
@en
Kevin M. Goode
@es
Kevin M. Goode
@nl
Kevin M. Goode
@sl
altLabel
K.M. Goode
@en
Kevin M. Goode
@en
prefLabel
Kevin M. Goode
@ast
Kevin M. Goode
@en
Kevin M. Goode
@es
Kevin M. Goode
@nl
Kevin M. Goode
@sl
P1053
J-6032-2013
P106
P1153
11439464800
P1960
Ao0xXdsAAAAJ
P2038
Kevin_Goode
P21
P2456
P31
P3829
P496
0000-0003-1963-345X